Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate

Mario Falsaperla, Giuseppe Morgia, Alfredo Tartarone, Raffaele Ardito, Giampiero Romano

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that determines poor quality of life (QoL) and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a polyphenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells. Endpoints: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine. Materials and Methods: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid. Results: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group A. On the contrary no significant difference in OS and PFS was detected between groups. Conclusions: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in particular neutropenia, in HRCP patients; however, further studies are required to confirm our results.

Original languageEnglish
Pages (from-to)449-454
Number of pages6
JournalEuropean Urology
Volume47
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Estramustine
Ellagic Acid
Prostatic Neoplasms
Phosphates
Hormones
Drug Therapy
Neutropenia
Therapeutics
Insulin-Like Growth Factor II
Survival
Neoplasm Genes
Polyphenols
S Phase
Down-Regulation
Antioxidants
Quality of Life
vinorelbine
Apoptosis
Pain
Control Groups

Keywords

  • Chemotherapy
  • Ellagic acid
  • Estramustine phosphate
  • Hormone refractory prostate cancer (HRPC)
  • Vinorelbine

ASJC Scopus subject areas

  • Urology

Cite this

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. / Falsaperla, Mario; Morgia, Giuseppe; Tartarone, Alfredo; Ardito, Raffaele; Romano, Giampiero.

In: European Urology, Vol. 47, No. 4, 04.2005, p. 449-454.

Research output: Contribution to journalArticle

Falsaperla, Mario ; Morgia, Giuseppe ; Tartarone, Alfredo ; Ardito, Raffaele ; Romano, Giampiero. / Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. In: European Urology. 2005 ; Vol. 47, No. 4. pp. 449-454.
@article{dcc118b66814490ea32ec2b63e9a39a3,
title = "Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate",
abstract = "Background: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that determines poor quality of life (QoL) and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a polyphenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells. Endpoints: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine. Materials and Methods: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid. Results: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group A. On the contrary no significant difference in OS and PFS was detected between groups. Conclusions: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in particular neutropenia, in HRCP patients; however, further studies are required to confirm our results.",
keywords = "Chemotherapy, Ellagic acid, Estramustine phosphate, Hormone refractory prostate cancer (HRPC), Vinorelbine",
author = "Mario Falsaperla and Giuseppe Morgia and Alfredo Tartarone and Raffaele Ardito and Giampiero Romano",
year = "2005",
month = "4",
doi = "10.1016/j.eururo.2004.12.001",
language = "English",
volume = "47",
pages = "449--454",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "4",

}

TY - JOUR

T1 - Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate

AU - Falsaperla, Mario

AU - Morgia, Giuseppe

AU - Tartarone, Alfredo

AU - Ardito, Raffaele

AU - Romano, Giampiero

PY - 2005/4

Y1 - 2005/4

N2 - Background: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that determines poor quality of life (QoL) and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a polyphenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells. Endpoints: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine. Materials and Methods: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid. Results: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group A. On the contrary no significant difference in OS and PFS was detected between groups. Conclusions: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in particular neutropenia, in HRCP patients; however, further studies are required to confirm our results.

AB - Background: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that determines poor quality of life (QoL) and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a polyphenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells. Endpoints: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine. Materials and Methods: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid. Results: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group A. On the contrary no significant difference in OS and PFS was detected between groups. Conclusions: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in particular neutropenia, in HRCP patients; however, further studies are required to confirm our results.

KW - Chemotherapy

KW - Ellagic acid

KW - Estramustine phosphate

KW - Hormone refractory prostate cancer (HRPC)

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=14844355240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844355240&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2004.12.001

DO - 10.1016/j.eururo.2004.12.001

M3 - Article

VL - 47

SP - 449

EP - 454

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -